Clinical trial · Observational
Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease
Research and Development Study: Tissue Collection From Patients Who Are Undergoing Surgery for Non-Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A 15-gene lung signature was created to identify predictive and prognostic biomarkers for Non-Small Cell Lung Cancer (NSCLC) patients. The 15-gene signature was validated using a microarray platform with fresh frozen tumor tissue to place NSCLC patients into high risk and low risk cohorts with significantly different survivals. Using fresh frozen tissue can be challenging, so this study attempts simplify the process by migrating the 15-gene signature from fresh frozen to two alternative tissue formats: Formalin Fixed Paraffin Embedded (FFPE) and RNAlater. The gene expressions of the different tissue formats will be compared to see if the fresh frozen tissue results are similar to the alternative tissue formats.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * New diagnosis of stage I or II Non-Small Cell Lung Cancer (NSCLC) * Must have resectable disease and complete surgical resection planned * Histologically or cytologically confirmed adenocarcinoma, squamous or large cell carcinoma NSCLC * No prior chemotherapy, biologic/molecular targeted therapy or radiation therapy for this cancer * Tumor specimen samples must be collected within 1 hour of surgery * Patient must be at least 18 years of age * Patient must sign and date an approved study consent form Exclusion Criteria: * Patients with psychiatric or addictive disorders that would preclude obtaining study consent * Informed consent obtained the same day as surgery * Absence of histological diagnosis of lung cancer * Known infectious disease * History of chemotherapy, biologic/molecular targeted therapy or radiation therapy for this cancer or any prior cancer or any other non-cancer diseases or illnesses, i.e. rheumatoid arthritis
References
Publications (0)
Data not yet available